Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 2,084 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer
Interventions: Vismodegib, FOLFOX, FOLFIRI, Bevacizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 10
States / cities: Scottsdale, Arizona • Oakland, California • Palm Springs, California + 7 more

Conditions: Healthy Volunteers
Interventions: Canagliflozin, 300 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg, CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis
Interventions: Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial, Spirometry, RNA Sequencing, Laboratory testing, Corticosteroid, Tofacitinib 5mg [Xeljanz] 1 year open-label extension; Drug · Diagnostic Test · Genetic
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: TTR-mediated Amyloidosis
Interventions: Revusiran (ALN-TTRSC); Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Cleveland, Ohio

Conditions: Basal Cell Nevus Syndrome
Interventions: Patidegib Topical Gel, 2%; Drug
Lead sponsor: Sol-Gel Technologies, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 17
States / cities: Fremont, California • Newport Beach, California • New Haven, Connecticut + 14 more

Conditions: HIV-1 Infection
Interventions: BIC, F/TAF, DTG, BIC Placebo, DTG Placebo, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more

Conditions: Treatment of Overactive Bladder
Interventions: Fesoterodine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Parkinson's Disease (PD)
Interventions: ABBV-951; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 15
States / cities: Birmingham, Alabama • Sun City, Arizona • Aurora, Colorado + 12 more

Conditions: Contraception
Interventions: DR-1011; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 2,235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 55
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more

Conditions: Seizures, Lennox Gastaut Syndrome
Interventions: Carisbamate; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 4 Years to 55 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 22
States / cities: Palo Alto, California • Jacksonville, Florida • Orlando, Florida + 18 more

Conditions: Systemic Lupus Erythematosus
Interventions: Epratuzumab; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 78
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Hemet, California + 63 more

Conditions: Diabetic Foot Ulcers
Interventions: Tissue, Control; Other
Lead sponsor: Osiris Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 15
States / cities: Montgomery, Alabama • Glendale, Arizona • Encinitas, California + 12 more

Conditions: Dementia With Lewy Bodies
Interventions: Neflamapimod, Placebo; Drug
Lead sponsor: EIP Pharma Inc; Industry
Eligibility: 55 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 29
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 26 more

Conditions: Dup15q Syndrome
Interventions: Basmisanil, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 14 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Los Angeles, California • Chicago, Illinois

Conditions: Bipolar Disorder, Mania
Interventions: divalproex sodium extended release; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 12 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Hemophilia A, Hemophilia B
Interventions: PF-06741086; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Year to 74 Years · Male only
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 4
States / cities: Iowa City, Iowa • New Hyde Park, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes, Behavioral Symptoms, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Abnormalities, Multiple, Congenital Abnormalities, Chromosome Disorders, Genetic Diseases, Inborn, Obesity, Overnutrition, Nutrition Disorders, Antihypertensive Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Physiological Effects of Drugs, Skin-Picking
Interventions: Guanfacine Extended Release, Placebo; Drug · Other
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 6 Years to 35 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Depression
Interventions: blood draw; Procedure
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 971 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 52
States / cities: Birmingham, Alabama • Tuscon, Arizona • Little Rock, Arkansas + 46 more

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Dinesh Khanna, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 23
States / cities: Los Angeles, California • Redwood City, California • Washington D.C., District of Columbia + 17 more

Conditions: Epilepsies, Partial
Interventions: Pregabalin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 1 Month to 16 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 16
States / cities: Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 9 more

Conditions: Peanut Allergy
Interventions: DBV712 250 mcg; Biological
Lead sponsor: DBV Technologies; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 26
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 22 more

Conditions: Migraine Disorders
Interventions: MAP0004, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Major Depressive Disorder (MDD)
Interventions: SSRI (escitalopram or sertraline), Extended-Release Memantine, Placebo; Drug
Lead sponsor: Jeffrey Miller; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: X-Linked Hypophosphatemia
Interventions: KRN23; Biological
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more

Search by objective public record fields.

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus

Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers

RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome

Study of Depakote ER for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl

A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis

Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

Phase 3 Study of MAP0004 in Adult Migraineurs

Pattern Separation in Major Depressive Disorder

Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)